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E-cadherin plays a major role in cell–cell adhesion and inactivating germline mutations in its encod-
ing gene predispose to hereditary diffuse gastric cancer. Evidence indicates that aside from its rec-
ognized role in early tumourigenesis, E-cadherin is also pivotal for tumour progression, including
invasion and metastization. Herein, we discuss E-cadherin alterations found in a cancer context,
associated cellular effects and signalling pathways, and we raise new key questions that will impact
in the management of GC patients and families.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Gastric cancer (GC) remains a major concern worldwide charac-
terized by an inherent molecular heterogeneity and consequent
divergent clinical biology [1]. According to the World Health
Organization (WHO) and the Laurén classiﬁcations, two main
histological types of GC can be described displaying distinct
clinicopathological features, the diffuse and intestinal subtypes
[1–3]. Diffuse type cancer is composed by non-cohesive cells (with
or without signet ring cells) and is more commonly observed in
younger patients [3,4]. In contrast, the intestinal type, believed to
occur through a multistep progression from multifocal atrophical Societies. Published by Elsevier
te of Molecular Pathology and
rto Frias s/n, 4200-465 Porto,gastritis, is characterized by glandular architecture (tubular and/
or papillary), and is frequently found in older patients [3,5].
Throughout the last few decades it has become obvious that GC
results from a complex interplay between genetics and environ-
ment [1,3]. Indeed, it has been well established that GC initiation
and progression involves accumulation of genetic alterations in a
myriad of genetic pathways, namely those involved in DNA repair,
cell adhesion, signal transduction, cell differentiation, and apopto-
sis, among others [6,7]. Furthermore, different genetic pathways
are thought to underlie the development of diffuse- and intesti-
nal-type GCs and given the heterogeneity and complexity of gastric
tumours, it is now widely accepted that genetic and epigenetic
alterations in the host contribute to the development of disease
in combination with environmental factors. Diffuse gastric cancer
(DGC) has a clear hereditary form and results from E-cadherin
deregulation upon genetic or epigenetic alterations [8], whereas
occurrence of intestinal type is more associated with environmen-
tal factors such as obesity, dietary factors, cigarette smoking, as
well as with infection by Helicobater pylori [1,3,9–11].B.V. Open access under CC BY-NC-ND license. 
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disease are often asymptomatic and the late onset of clinical symp-
toms awards GC patients a poor prognosis [3,12]. Furthermore,
curative therapy is only possible upon complete resection of the
tumour, usually accomplished with a complete gastrectomy,
although subtotal resection of the stomach can be performed
depending on the tumour location [13]. In Western countries, it
is estimated that 80–90% of GC patients are either diagnosed at
an advanced stage when the tumour is no longer operable or devel-
op recurrence within 5 years of surgery [12].
A common and perhaps the most relevant feature of all tumours
is the ability of cancer cells to detach from the primary tumour and
invade neighbouring and distant sites leading to the formation of
metastases and progression of tumour malignancy [14,15]. This
capacity arises as cells lose the ability to be adherent and gain an
increased potential to invade, a process highly associated to loss
of expression of E-cadherin (epithelial cadherin) [16–18]. E-cad-
herin is a Ca2+-dependent cell–cell adhesion molecule essential
for the establishment of epithelial architecture and maintenance
of cell polarity and differentiation, both during development and
in adult life [19,20]. Extensive research provided evidence that E-
cadherin is a broad-acting tumour suppressor, and indeed it is re-
garded as a major determinant of tumour progression and invasion
in epithelial cancers, namely gastric carcinomas [14,20].
In this paper we aim to provide a state of the art report regard-
ing E-cadherin function and dysfunction with speciﬁc emphasis on
its involvement in GC development and open new avenues in this
ﬁeld of research.
2. E-cadherin structure and function
The prototypical member of the cadherin superfamily was ﬁrst
identiﬁed in 1977 by Takeichi as a surface protein with a Ca2+-
dependent cell–cell adhesion potential [19,21]. This single-pass
transmembrane glycoprotein is encoded by the CDH1 gene, anno-
tated to the human chromosome 16q22.1 in a cluster along with
other cadherins [22]. Transcription is currently annotated at the
coordinate 68,771,128 bp and translation (ATG) starts 194 bp
downstream [23]. Although the canonical CDH1 promoter does
not contain a TATA box, it displays the highly conserved regulatory
elements GC boxes, E boxes and a CCAAT box [19,20].
The mature E-cadherin protein is organized in three major
structural domains: a cytoplasmic domain of about 150 amino acid
residues (AA), a single transmembrane domain and an extracellular
domain of about 550 AA, comprising ﬁve tandemly repeated do-
mains exclusive to cadherins, the so-called EC1–EC5 [8,24].
The epithelial cell-cell adhesion is achieved through homophilic
interactions between cadherin molecules, ﬁrst among adjacent
cells (trans-interaction) and then within the same cell by lateral
association (cis-interaction), leading to the formation of zipper-like
structures [25–27]. Furthermore, E-cadherin conformation is only
stable upon Ca2+ binding to highly conserved repeats, negatively
charged motifs present in the extracellular domain [28,29]. The
cytoplasmic domain of E-cadherin interacts with b-, a-, and c (pla-
koglobin)-catenins (bctn, actn, cctn), with actn anchored to the ac-
tin cytoskeleton, thus establishing the cadherin-catenin complex
[30]. E-cadherin stabilization at the cell membrane and accurate
function occurs by association to p120-catenin (p120ctn), which
not only accelerates the delivery or recycling of cadherins to the
plasma membrane but it also prevents E-cadherin from entering
the degrading endocytic trafﬁcking pathway [19,31,32]. The stabil-
ity of the cadherin-catenin complex, and its linkage to actin ﬁla-
ments, forms the core of the Adherens Junction (AJ), which is
vital to inhibit individual epithelial cell motility and to provide
homeostatic tissue architecture [8,18].3. Role of E-cadherin in development
During differentiation processes like gastrulation, neurulation
or neurite outgrowth, cell–cell and cell-matrix adhesion must be
ﬁrm but also ﬂexible enough to allow cell migration and morpho-
genesis [33]. Indeed, E-cadherin is expressed in all mammalian epi-
thelia and is one of the ﬁrst adhesion molecules expressed in the
mouse embryo. Interestingly, ovumorulin, as it was originally
named, was identiﬁed at the one cell stage embryo [34,35], and
in the preimplantation mouse embryo, at the 8-cell stage, E-cad-
herin was shown to be essential during morula compaction and
subsequent epithelial tissue organization [36]. During fetal devel-
opment, E-cadherin is only expressed in the embryonic region of
the placenta and has been awarded a key role in maintaining a spa-
tial boundary between embryonic and maternal tissues [35,37,38].
E-cadherin knockout (KO) in mice is lethal at embryonic day 4
(E4), resulting in junctional and cytoskeletal organization defects
and, ultimately, in failure to form trophoectoderm, the ﬁrst polar-
ized epithelial layer in the mouse embryo, thus demonstrating its
relevance during normal development [39]. Furthermore, germline
mutations in CDH1 have been associated to congenital midline
malformations and, in fact, it was proposed that speciﬁc E-cadherin
alterations during development may underlie the genesis of cra-
niofacial congenital malformations, such as lip and palate cleft
[40].
4. E-cadherin regulatory mechanisms
The pivotal role of E-cadherin in speciﬁc developmental pro-
cesses as well as its function during carcinogenesis, discussed be-
low, is reﬂected in the complexity of mechanisms regulating E-
cadherin epithelium-speciﬁc expression. Indeed, E-cadherin
expression is regulated at many levels, from gene expression to
transport and protein turnover at the cell surface [8,41]. During
development, many transcriptional repressors have been reported
to bind to the E-boxes, inducing downregulation of E-cadherin,
namely the zinc-ﬁnger proteins of the Snail/Slug superfamily, as
well as ZEB1 and ZEB2 [8,42–46]. Another relevant mechanism
leading to silencing of E-cadherin is promoter hypermethylation,
which has been associated to tumour progression [47–50].
E-cadherin expression is also controlled through positive regu-
latory elements in the CDH1 50 sequence. Examples of activators of
E-cadherin are: the hepatocyte nuclear factor-3 (HNF3), the zinc-
ﬁnger protein WT1 and the transcription factor AP2 [51]. AP2 binds
to E-cadherin promoter region, and the retinoblastoma protein
(Rb) as well as the proto-oncogene product c-Myc act as co-activa-
tors of AP2 in epithelial cells [19].
The exocytic trafﬁcking pathway is fundamental for the correct
transport of newly synthesized E-cadherin to the plasma mem-
brane [52]. Once delivered to the cell surface, E-cadherin is regu-
lated by phosphorylation, ubiquitination and proteolysis [53,54].
Integrity of the cadherin/catenin complex is known to be regu-
lated, both positively and negatively, by phosphorylation. Phos-
phorylation of bctn by tyrosine kinases, such as Src or other
tyrosine kinase receptor (RTK) disrupts the binding to E-cadherin,
which is then targeted for degradation [55]. In contrast, serine
phosphorylation in the E-cadherin molecule results in an increased
afﬁnity to bctn [56]. O-glycosylation of the E-cadherin cytoplasmic
domain has been reported as a mechanism impairing its transport
to the cell surface [57], whereas N-glycosylation of E-cadherin is
essential for its folding and trafﬁcking [58,59].
Upon its delivery to the membrane, E-cadherin faces another le-
vel of regulation, the endocytic pathway, which leads to either its
recycling to the plasma membrane, to its transient sequestration
inside the cell or to its degradation [54]. Many potential regulators
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ribosylation factor 6 (Arf6) [60,61] and the E3 ubiquitin ligase
Hakai [62]. Interestingly, E-cadherin ubiquitination mediated
by Hakai also involves epidermal growth factor receptor (EGFR)
activation and Src signalling by Cdc42 [63]. Furthermore, lyso-
somal targeting of E-cadherin is thought to involve the endosomal
sorting activity of HGF-regulated tyrosine kinase substrate (Hrs), as
well as Src activation of the GTPases Rab5 and Rab7 [64]. In con-
trast, p120ctn has been reported as an inhibitor of E-cadherin
endocytosis, by blocking adaptor complexes for clathrin-mediated
endocytosis [65].
5. E-cadherin dysfunction and gastric cancer
It comes as no surprise that genetic or epigenetic alterations in
E-cadherin leads to disturbed epithelial cell-cell adhesion and
structure, aberrant stromal interactions, as well as altered cell
migration and signalling, with ultimate oncogenic potential [66].
Indeed, functional loss of E-cadherin is a well established molecu-
lar event that occurs during tumour progression, leading to in-
creased invasion of cancer cells to neighbouring tissues and to
metastasis [67,68]. More so, reduced expression of E-cadherin,
mostly due to decreased expression at mRNA and protein levels,
is regarded as indicative of poor outcome in a variety of malignan-
cies. In fact, only a minor proportion of advanced carcinomas pres-
ent CDH1 mutations [14,69]. CDH1 is however regarded as a
classical tumour suppressor gene in gastric carcinogenesis, being
involved in the initiation and progression of both sporadic and
hereditary forms of GC [70,71]. Of relevance, inherited germline
mutations in CDH1 are a causative feature of hereditary diffuse
gastric cancer (HDGC), awarding E-cadherin as the culprit for the
development of this cancer syndrome [72].
HDGC was the ﬁrst gastric cancer-related disease, identiﬁed
upon reports of three Maori kindred displaying early onset, mul-
tigenerational DGC associated with germline mutations of the E-
cadherin gene [73]. Ever since, increasing evidence has further
supported a speciﬁc role of E-cadherin in the initiation of DGC,
and indeed over 40% of HDGC cases present CDH1 germline
mutations [72,74–76]. In 1999, the International Gastric Cancer
Linkage Consortium (IGCLC) deﬁned the clinical criteria for iden-
tiﬁcation of HDGC [77], characterized by highly penetrant dif-
fuse-type GC (80% lifetime risk) and elevated risk of lobular
breast cancer [72,76]. Familial aggregations with high incidence
of GC and with an index case of DGC, although not fulﬁlling
the IGCLC criteria for HDGC, are classiﬁed as familial diffuse gas-
tric cancer (FDGC) [4]. Despite that HDGC accounts for only a
small subset of GCs (1–3%), it represents a major health issue
due to its severity, high penetrance and inefﬁcient surveillance
tools [76], and an interesting natural model to unravel E-cad-
herin-dependent signalling pathways. In addition to the germline
CDH1 mutations observed in inherited DGCs, approximately 50%
of sporadic invasive lobular breast carcinomas and diffuse gastric
adenocarcinomas display somatic inactivating CDH1 mutations
[78–80].
Germline mutations in CDH1 have indeed been reported in dif-
fuse early onset gastric cancer (EOGC) patients with and without
family history of GC [81]. Corso and colleagues have recently de-
scribed a summary of apparently sporadic diffuse or mixed cases
revealing that, in fact, 7.2% in fact carried CDH1 germline muta-
tions, of which 2.3% were predicted to be deleterious [81].
Remarkably, Masciari et al. reported CDH1 germline mutations
associated with invasive lobular breast cancer in the absence of
DGC, despite that it is widely accepted that CDH1 germline muta-
tions are infrequent in women with early-onset or familial lobular
breast cancers independently of DGC association [82,83].6. Molecular deregulation of E-cadherin
To date, 122 germline mutations have been described in the
CDH1 gene [84], and although there are no major mutational hot-
spots, some mutations (1003C > T, 1901C > T and 1137G > A) have
been consistently identiﬁed in unrelated kindred [72]. In a recent
metanalysis by Corso et al., a signiﬁcant association was found be-
tween CDH1 mutation frequency and low-risk areas for GC. Specif-
ically, from a set of 122 CDH1 germline mutations, 87.5% arose
from low-risk areas, although the majority of which were of the
non-missence-type, whereas in high-risk areas, missense muta-
tions were predominant (11/16; 68.8%). This interesting ﬁnding
suggests that ethnicity of GC patients should be considered a sig-
niﬁcant risk factor for gastric carcinoma and conﬁrms that GC in-
deed presents various clinic-pathologic and molecular features
[84]. Strikingly, germline CDH1mutations are rarely found in coun-
tries such as Japan and Korea [72], although this effect can be re-
lated to the high rates of sporadic GC found in these countries.
The most common types of CDH1 germline mutations are small
frameshift insertions and deletions, as well as point mutations,
with 80% resulting in protein truncation or even complete loss of
expression. The remaining 20% of CDH1 germline alterations are
of the missense type [85–89], whose pathogenic relevance and
functional assessment implicates a myriad of in silico and in vitro
functional assays developed by our group [90–93]. Additionally,
we reported for the ﬁrst time in 2009, germline CDH1 large geno-
mic deletions in apparently mutation negative HDGC families [74].
Somatically, E-cadherin mutations are mainly splice site mutations
resulting in exon skipping (frequently exons 8 or 9) [78,94].
Development of DGC in patients harbouring CDH1 mutations
(hereditary and sporadic) occurs upon a ‘‘2nd-hit’’ mechanism
that leads to E-cadherin aberrant or absent expression [95–
97]. Hypermethylation in a large CpG island in the CDH1 50
proximal promoter is an important epigenetic event associated
with loss of E-cadherin gene expression and occurs in a myriad
of carcinomas [66,98]. In HDGC tumours, hypermethylation of
the CDH1 promoter is considered the most common mechanism
associated to biallelic CDH1 inactivation, accounting for 50%–
70% of the cases. Moreover, our group has reported that loss
of heterozygosity (LOH) represents a key mechanism in meta-
static lesions from HDGC patients [49,95]. In sporadic forms
of diffuse gastric carcinomas, promoter methylation is also re-
garded as the most frequent ‘‘2nd-hit’’ inactivating mechanism
[80].
Despite the widespread belief that classical CDH1 inactivation
mechanisms are predominantly associated to diffuse-type of GCs,
abnormal E-cadherin expression has been reported in the majority
of GCs of both diffuse and intestinal types [99]. MicroRNAs (miR)
have emerged as a potential mechanism regulating CDH1 expres-
sion thus contributing to gastric carcinogenesis [100], and for in-
stance, members of the miR-200 family have been associated to
regulation of E-cadherin expression, by targeting the transcrip-
tional repressors ZEB1 and ZEB2 [101,102]. Strikingly, our group
has recently identiﬁed miR-101 down-regulation as a new mecha-
nism underlying E-cadherin inactivation mainly in intestinal-type
tumours [103].
Aside from genetic and epigenetic silencing of E-cadherin,
many other mechanisms can account for E-cadherin dysfunction
during pathological conditions. Aberrant regulation of E-cadherin
trafﬁcking pathways lead to disruption of its function and, conse-
quently, to pathophysiological conditions, such as malignant trans-
formation and cancer metastases [54]. Accordingly, we recently
demonstrated the relevance of E-cadherin trafﬁcking deregulation
in two E-cadherin missense mutations associated to HDGC [104].
We showed that mutant E-cadherin is targeted for proteasomal
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ciated Degradation (ERAD) machinery [104].
E-cadherin dysfunction during tumour development and pro-
gression has also been associated to N-glycosylation and O-glyco-
sylation modiﬁcations [58,105]. Particularly, we have reported
aberrant N-glycosylation modiﬁcations associated to E-cadherin
deregulation in human breast and GCs [106]. On the other hand,
abnormal activation of proto-oncogenes, including c-Met and Src,
has also been shown to result in increased phosphorylation of tyro-
sine residues in the cytoplasmic domain of E-cadherin, leading to
the recruitment of Hakai and subsequent ubiquitin-degradation
of E-cadherin [62].
7. E-cadherin mediated tumour spectrum
CDH1 germline mutations confer more than 80% lifetime risk to
speciﬁcally develop GC, albeit that E-cadherin is ubiquitously ex-
pressed in all epithelial tissues. However, the tissue speciﬁc molec-
ular determinants behind the predominant increased risk for
stomach cancer remain to be uncovered. Our group has previously
reported that GC cells silenced for E-cadherin are more resistant to
pro-apoptotic stimulus than control cells, in a Notch signalling-
dependent manner [107,108]. Moreover, extensive analysis of nor-
mal tissues expression arrays further revealed that 40% of normal
gastric-speciﬁc genes are involved in survival/apoptosis, most of
which have been reported to be deregulated in GC, such as the Tre-
foil Factor Family 1 (TFF1) [109]. Thus, we hypothesize that in the
stomach, cells negative for E-cadherin are able to overcome apop-
tosis and ultimately become more prone for transformation due to
a speciﬁc genetic programme or to microenvironmental settings.
Our preliminary data indicates that cumulative activation of Notch
and gastric-speciﬁc genes may be underlying the ability of gastricFig. 1. Schematic overview of proposed mechanisms of CDH1 regulation and E-cadherin
deregulated at various levels in gastric cancer. CHD1 inactivating mutations, promoter
frequently found in gastric cancer. Aberrant E-cadherin expression will in turn promote d
adhesion, migration, invasion and survival. The network of signalling pathways that inte
MMPs.cells to overcome E-cadherin mediated apoptosis in contrast to
other tissues (unpublished).
8. E-cadherin related signalling pathways
Throughout the past decades many molecules and signalling
pathways have been associated to E-cadherin regulation and func-
tion. Increasing evidence suggests that a network of signalling
pathways intersects with E-cadherin and these are known to in-
volve a multitude of molecules including EGFR, Notch-1, Bcl-2,
Rho family members and matrix metalloproteinases (MMPs) as
illustrated in Fig. 1. Aberrant E-cadherin will therefore promote
deregulation of E-cadherin-mediated signalling pathways, having
an impact in cell-cell adhesion, migration, invasion and survival
[8].
As an adhesion molecule, E-cadherin interacts with a wide
range of cellular partners as catenins, integrins, growth factor
receptors and cytoskeletal components to mediate intracellular
signalling and modulate the organization of the cytoskeleton, cru-
cial for the maintenance of cell polarity [110]. Of particular interest
is the convergence of the bctn and cadherin pathways. In addition
to its central role as an adaptor protein linking cadherins to the ac-
tin cytoskeleton in cell-cell adhesion, bctn is also a key player in
the Wnt signaling, acting as a transcription cofactor with T cell fac-
tor/lymphoid enhancer factor (TCF/LEF) [111]. However, the role of
E-cadherin in modulating the Wnt/ bctn remains to be dissected.
Results from our group have shown that E-cadherin mutants
affecting the bctn binding domain, and resulting in E-cadherin loss
of function, do not lead to nuclear accumulation of bctn or in-
creased cell proliferation, suggesting that the effect of the E-cad-
herin mutants does not induce the activation of the Wnt
pathway in a bctn-dependent way [112].mediated signalling pathways involved in gastric cancer. E-cadherin expression is
methylation and transcriptional regulation, through activators and repressors, are
eregulation of E-cadherin-mediated signaling pathways having an impact in cell-cell
rsects with E-cadherin involves, among others, Rac1, RhoA, EGFR, Notch, Bcl-2, and
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volves Rho GTPases, known to play a role in cytoskeletal organiza-
tion. For instance, Rac1 and RhoA were shown to be overexpressed
in primary gastric carcinoma [113]. Furthermore, increased RhoA
activity, which led to higher migration capacity, was induced by
HDGC-associated extracellular E-cadherin missense mutations
[90,114]. Moreover, EGFR has been shown to be involved in RhoA
activation in an E-cadherin-dependent manner [114,115]. Notice-
ably, we demonstrated that mutations at the E-cadherin extracel-
lular domain impair the EGFR/E-cadherin interaction, leading to
EGFR activation, and enhanced cell motility through activation of
RhoA [114].
As for EGFR, other pathways relevant for cell motility such as
Src kinase and p38 MAPK have been shown to be aberrantly acti-
vated as a consequence of HDGC-related E-cadherin mutations
[116]. In addition, alterations in the expression of MMPs, impor-
tant to modulate the surrounding extracellular matrix (ECM) and
facilitate tumour invasion and metastasis, have also been de-
scribed in GC. For instance, reduced expression of E-cadherin and
increased expression of MMP1 and MMP2 was found in GC tissues,
for which E-cadherin loss and MMP2 expression was strongly cor-
related with deeper tumor invasion [117]. Likewise, a negative cor-
relation between MMP9 and E-cadherin was found in a set of
gastric carcinomas [118]. A functional link between MMP3 and
E-cadherin has also been found in transfected cells showing that
MMP3 is differentially regulated by expression of the wild type
or mutant E-cadherin variants, with subsequent effects on cell
motility [119]. In addition, using in vitro models, our group ob-
served a regulation of MMP activity by E-cadherin. Mutant E-cad-
herin cells secreted higher levels of MMP9, in contrast to cells
expressing the wild type protein (unpublished data). Of particular
interest is the fact that E-cadherin can be suppressed by MMPs,
through cleavage in the E-cadherin extracellular domain, thus add-
ing an extra level of control in the invasion process [120].
E-cadherin has also been shown to be involved in apoptosis and
cell survival. Indeed, we have shown that functional loss of E-cad-
herin renders cells more resistant to apoptotic stimuli [107]. Strik-
ingly, using in vitro and in vivo studies, we have demonstrated that
E-cadherin impairment is able to increase cell survival through
Notch-dependent upregulation of Bcl-2 [108].
9. Pathogenesis of Helicobacter pylori
H. pylori infection is widely regarded as a major ethiologic factor
for the development of gastric carcinoma [121]. Mounting evi-
dence has associated this bacterial pathogen with the epigenetic
silencing of E-cadherin [122,123] and with other mechanisms
responsible for its deregulation, namely cleavage of E-cadherin
extracellular domain by ADAM10 or by the secreted bacterial pro-
tease HtrA [124,125] and, although controversial, translocation of
E-cadherin/catenin complex proteins from the membrane to intra-
cellular locations [126–128]. Interestingly, our group has demon-
strated that, in E-cadherin wild type cells, H. pylori infection
promotes the formation of a multiproteic complex containing c-
Met and E-cadherin, impairing H. pylori induced c-Met-mediated
signaling [129]. However, in E-cadherin defective GC cells H. pylori
infection induces c-Met activation and increases the activity of
MMP2 and MMP9, thus leading to ECM degradation and subse-
quent cell invasion, which may contribute to the increased suscep-
tibility for H. pylori-infected individuals to develop GC [130].
10. In vivo cancer models
Thus far, the most compelling in vivo evidence supporting the
causal relationship between E-cadherin loss of function and initia-tion of DGCwas reported by Humar et al. in 2009. For the ﬁrst time,
the authors successfully induced signet-ring cell carcinomas
(SRCCs) in CDH1+/- mice using a known stomach carcinogen (N-
methyl-N-nitrosourea) [75]. Other reports include a conditional
E-cadherin KO targeted to stomach parietal cells. Although clusters
of signet ring-like cells were found, no invasive gastric adenocarci-
nomas were observed in E-cadherin-deﬁcient mice, reinforcing the
idea that other interactors may be involved in E-cadherin-medi-
ated DGC development [131]. Just recently, Shimada and co-work-
ers established the ﬁrst genetically engineered mouse model of
DGC through conditional KO mice for both E-cadherin and p53.
The animals displayed intramucosal and invasive cancers com-
posed of poorly differentiated carcinoma and signet-ring cells,
and furthermore, their gene expression proﬁles resembled those
of human patients [132].
Other in vivo studies aimed to unravel how E-cadherin’s loss can
lead to metastases, namely ovary metastases as described in HDGC
patients. In mice, human GC cell lines displaying abnormal E-cad-
herin expression lead to ovary metastases, and the rescue of E-cad-
herin expression completely inhibited the ovarian-metastatic
phenotype, without interfering with the metastatic ability to other
organs [133].
The study of HDGC-associated E-cadherin missense mutations
has also been successfully undertaken using fruitﬂies. Expression
of these mutated proteins in the Drosophila wing epithelium mim-
icked the in vitro results, both in terms of migration and invasion
[134]. A Drosophila approach to screen for novel GC-related genes
was recently reported by our group in a background sensitized
by E-cadherin mutations [135].
Conversely, rescue of E-cadherin expression in cancer cell lines
and in transgenic mice models of carcinogenesis impaired invasion
and reversed poorly differentiated carcinoma phenotypes to a
well-differentiated epithelioid phenotype, providing mounting evi-
dence for the tumour suppressor role of E-cadherin [136–138].
11. Pro-oncogenic role of soluble E-cadherin
The identiﬁcation of E-cadherin as tumour suppressor is
undoubtedly associated to the predisposition to both diffuse gas-
tric and lobular breast cancers in patients harbouring mutations
in the CDH1 gene [139]. Furthermore, the widespread notion is that
epithelial-mesenchymal transition (EMT) induction and loss of E-
cadherin is a prerequisite for metastasis and disease progression.
However, it has been suggested that E-cadherin may play alterna-
tive roles in tumour progression, namely through stabilization of
cell contacts during ‘‘collective cell migration’’ [140], as well as
aberrant cytoplasmic and nuclear signalling [18]. Proteolytic cleav-
age and release of soluble E-cadherin fragments is proposed to ex-
ert a pro-oncogenic effect enhancing tumour growth, survival and
motility [18,68]. The clinical detection of elevated soluble E-cad-
herin fragment (sE-cad) in the sera of cancer patients with poor
prognosis may award sE-cad a prognostic value for invasive and/
or metastatic disease. Nonetheless, this remains a controversial
subject and in fact, a study by Pedrazzani et al. suggests that sE-
cad should not be recommended in the diagnosis and management
of GC patients, since they observed a correlation between E-cad-
herin serum levels and age [141].
In contrast to normal cells where E-cadherin degradation is reg-
ulated by endocytosis, in cells undergoing apoptosis, proteolysis of
E-cadherin occurs by MMPs, namely ADAM10 and ADAM15, which
have been reported to be upregulated in a variety of cancers
awarding E-cadherin cleavage fragments a potential ‘‘tumourigen-
ic’’ role [68,142]. Nonetheless, systematic and rigorous research is
still lacking to describe the speciﬁc mechanisms underlying the
putative role of E-cadherin in tumour promotion.
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According to the recommendations of the IGCLC, prophylactic
gastrectomy should be offered to asymptomatic carriers of CDH1
truncating germline mutations, as the role of endoscopic surveil-
lance in clinical management of the disease remains controversial.
Indeed, the identiﬁcation of small foci of signet-ring cell gastric car-
cinoma (early DGCs) in prophylactic gastrectomy specimens, from
asymptomatic mutation carriers not yet displaying endoscopic evi-
dence of disease, raises concerns regarding the efﬁcacy of the cur-
rent surveillance protocols [72,91,143]. Despite its limitations,
endoscopic surveillance is still recommended for mutation carriers
younger than 20 years old or for those who decline or delay pro-
phylactic surgery, and should be carried out annually [72].
In hereditary forms of GC, carriers of CDH1 germline missense
mutations represent a major burden in terms of genetic counsel-
ling and clinical management, and thus, there have been increasing
efforts to predict the pathogenic signiﬁcance of CDH1 germline
missense variants. Noticeably, a multidisciplinary approach involv-
ing the study of mutation co-segregation with disease within ped-
igrees, frequency in healthy population controls, recurrence in
unrelated families, as well as in silico and functional in vitro assays
is currently used to identify high-risk individuals for HDGC
[74,85,91,92]. Moreover, very recently, we have reported a comple-
mentary method using proximity ligation assays (PLA) to assess
the interplay between E-cadherin missense mutants and regulators
of E-cadherin trafﬁcking, thus unveiling the pathogenicity of E-cad-
herin missense mutations [93]. Currently, we are developing bioi-
maging tools to determine the proﬁle of E-cadherin expression at
the cellular level. This analysis will extract morphological and tex-
tural features from immunoﬂuorescence images and will allow the
characterization of wild type and mutant E-cadherin expression.
13. Therapeutic approaches to E-cadherin mediated tumours
As discussed above, aberrant or absent E-cadherin expression in
the majority of GCs is consistent with bi-allelic dysfunction of the
CDH1 gene. Accordingly, the identiﬁcation of putative targets to re-
store E-cadherin expression has been a continuous challenge. DNA
demethylating agents in combination with other epigenetic drugs
(such as HDAC inhibitors) are potentially attractive to control the
development of disease given that they would prevent new DNA
methylation events as well as inhibit other epigenetic events
which may precede promoter hypermethylation, such as histone
modiﬁcation [144,145]. This type of approach expected to restore
CDH1 expression seems applicable only in small foci of the primary
tumour displaying epigenetic alterations. In contrast, genetic alter-
ations usually acquired as the tumour progresses could be targeted
with drugs such as EGFR and Notch inhibitors which have been
shown to suppress cell apoptosis, migration and metastasis
[108,114,146].
14. Concluding Remarks
E-cadherin has been awarded a key role during metazoan
development, where coordinated cell-cell adhesion is required
for proper establishment of the body plan and integrity of tissue
differentiation. Mounting evidence has arisen over the last
decades establishing E-cadherin as a tumour suppressor, and in
fact, suppression of E-cadherin function and/or expression has
been widely associated to an EMT phenotype and increased cell
migration and invasion [66,147]. Strikingly, E-cadherin germline
mutations have been identiﬁed in a large subset of HDGC
kindred and are nowadays regarded as the cause underlying
DGC development [73,76].The recognition of E-cadherin as a key molecule at the intersec-
tion of cell-cell adhesion, cell morphology and polarity, and cell life
and death, has awarded E-cadherin a leading position in cancer ini-
tiation and progression. Understanding and identifying the under-
lying molecular mechanisms of cadherin-dependent signalling will
undoubtedly have an impact in the clinical management of cancer
patients, namely GC patients, and in the identiﬁcation of most
effective molecular targets for treatment.
Future research should focus in the quest for other tumour sup-
pressor genes and oncogenes expected to play a cumulative role,
along with E-cadherin, in the pathophysiology of GC. The develop-
ment of new bioimaging tools to survey carriers of E-cadherin
germline mutations should also be on the spotlight, as well as
effective therapeutic regimens to treat patients with carcinomas
mediated by E-cadherin alterations at an early stage of disease
progression.
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